Smith Salley Wealth Management Buys 147 Shares of Danaher Corporation $DHR

Smith Salley Wealth Management raised its stake in shares of Danaher Corporation (NYSE:DHR) by 9.9% during the 2nd quarter, HoldingsChannel.com reports. The firm owned 1,635 shares of the conglomerate’s stock after acquiring an additional 147 shares during the quarter. Smith Salley Wealth Management’s holdings in Danaher were worth $323,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds also recently made changes to their positions in the company. GHP Investment Advisors Inc. increased its holdings in shares of Danaher by 396.0% during the 1st quarter. GHP Investment Advisors Inc. now owns 124 shares of the conglomerate’s stock worth $25,000 after purchasing an additional 99 shares during the period. Sierra Ocean LLC boosted its position in shares of Danaher by 116.9% during the 1st quarter. Sierra Ocean LLC now owns 141 shares of the conglomerate’s stock valued at $29,000 after acquiring an additional 76 shares in the last quarter. Smallwood Wealth Investment Management LLC acquired a new stake in shares of Danaher during the 1st quarter valued at about $31,000. Dunhill Financial LLC boosted its position in shares of Danaher by 68.4% during the 1st quarter. Dunhill Financial LLC now owns 165 shares of the conglomerate’s stock valued at $34,000 after acquiring an additional 67 shares in the last quarter. Finally, Costello Asset Management INC acquired a new stake in shares of Danaher during the 1st quarter valued at about $41,000. Institutional investors own 79.05% of the company’s stock.

Danaher Price Performance

Shares of DHR stock opened at $184.97 on Monday. Danaher Corporation has a 1 year low of $171.00 and a 1 year high of $279.59. The firm’s 50 day moving average is $199.44 and its 200-day moving average is $197.48. The firm has a market capitalization of $132.45 billion, a price-to-earnings ratio of 39.36, a PEG ratio of 2.63 and a beta of 0.75. The company has a current ratio of 1.62, a quick ratio of 1.22 and a debt-to-equity ratio of 0.32.

Danaher (NYSE:DHR) last announced its earnings results on Tuesday, July 22nd. The conglomerate reported $1.80 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.64 by $0.16. Danaher had a net margin of 14.21% and a return on equity of 10.70%. The company had revenue of $5.94 billion for the quarter, compared to analyst estimates of $5.83 billion. During the same period in the prior year, the business earned $1.72 earnings per share. Danaher’s quarterly revenue was up 3.4% on a year-over-year basis. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. Sell-side analysts forecast that Danaher Corporation will post 7.63 EPS for the current fiscal year.

Danaher Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, October 31st. Stockholders of record on Friday, September 26th will be given a dividend of $0.32 per share. This represents a $1.28 dividend on an annualized basis and a dividend yield of 0.7%. The ex-dividend date is Friday, September 26th. Danaher’s dividend payout ratio is presently 27.23%.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on DHR shares. Deutsche Bank Aktiengesellschaft decreased their target price on shares of Danaher from $240.00 to $235.00 in a research report on Thursday, June 5th. UBS Group decreased their target price on shares of Danaher from $240.00 to $225.00 and set a “buy” rating on the stock in a research report on Wednesday, July 23rd. Wells Fargo & Company decreased their target price on shares of Danaher from $210.00 to $205.00 and set an “equal weight” rating on the stock in a research report on Wednesday, July 23rd. Royal Bank Of Canada set a $241.00 price target on shares of Danaher in a research report on Tuesday, September 2nd. Finally, Robert W. Baird boosted their price target on shares of Danaher from $225.00 to $226.00 and gave the company an “outperform” rating in a research report on Friday, July 18th. Seventeen analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $245.91.

Insider Activity

In other news, Director Teri List sold 2,778 shares of the company’s stock in a transaction that occurred on Friday, August 22nd. The shares were sold at an average price of $211.06, for a total transaction of $586,324.68. Following the transaction, the director directly owned 20,751 shares in the company, valued at approximately $4,379,706.06. This represents a 11.81% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 11.20% of the company’s stock.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.